Balanced news tone
News Sentiment
VRXA sentiment intelligence
Veraxa Biotech AG Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+7.8% over one week, -89.0% over four weeks, trend inactive, and below fair value.
Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 18:40
- Source
- NewMediaWire
VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 19:30
- Source
- NewMediaWire
Veraxa partners with Ardigen on AI-driven cancer target selection
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 13 Jul 2026 15:18
- Source
- Investing.com UK
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 11:00
- Source
- GlobeNewswire
AI partnership aims to sharpen cancer target selection at VERAXA
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 13 Jul 2026 11:00
- Source
- Stock Titan
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:05
- Source
- GlobeNewswire
VERAXA Biotech (VRXA) Advances Lead BiTAC(R) T-Cell Engager Program With Cell Line Development Partnership
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Jul 2026 18:30
- Source
- NewMediaWire
VRXA Price History for Veraxa Biotech Ag Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 07:00
- Source
- Barchart.com
VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 03:14
- Source
- Quiver Quantitative
VERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 19:00
- Source
- NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 16:13
- Source
- The Globe and Mail
The Cancer Therapy Strategy VERAXA Is Betting the Company On
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 16:00
- Source
- Exec Edge
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 11:00
- Source
- GlobeNewswire
VERAXA says its BiTAC cancer pipeline is drawing partner interest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- Stock Titan
Veraxa Biotech Holding (VRXA) Stock Analysis Report | Financials & Insights
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- Benzinga España
VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 19:30
- Source
- NewMediaWire
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Market source
VERAXA advances lead cancer drug toward manufacturing work with ATUM
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Stock Titan
VERAXA adds 60% more lab space in Heidelberg for cancer drug work
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Financial Health: Profitability & Balance Sheet Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 17:14
- Source
- TradingKey
VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Barchart.com
VRXA SEC Filings - Veraxa Biotech AG 10-K, 10-Q, 8-K Forms
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA)
- Tone
- Positive 60/100
- Event
- Deals and strategy
- Published
- 17 Jun 2026 07:00
- Source
- Seeking Alpha
Veraxa Biotech AG (VRXA) Revenue Breakdown - Main Composition
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jun 2026 09:21
- Source
- Moomoo
Free cash flow per share of Veraxa Biotech AG – NASDAQ:VRXA
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 12 Jun 2026 18:56
- Source
- TradingView
Veraxa Biotech AG Financial Statements – NASDAQ:VRXA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 15:35
- Source
- TradingView
VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- The Globe and Mail
VERAXA Biotech (VRXA) Is 'One to Watch'
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Market source
VERAXA Biotech (NASDAQ: VRXA) Is ‘One to Watch’
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Barchart.com